The STEP-1 Extension Data Should Change How We Open Every Semaglutide Conversation

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for The STEP-1 Extension Data Should Change How We Open Every Semaglutide Conversation

The evidence base

The STEP-1 extension trial by Wilding et al., published in Diabetes, Obesity and Metabolism in 2022, followed 327 participants who had completed the 68-week STEP-1 randomized controlled trial and then entered a 52-week off-treatment follow-up. The finding was stark: participants regained a mean 11.6 percentage points of body weight during the withdrawal year, recovering approximately two-thirds of the weight they had lost on semaglutide 2.4 mg. Cardiometabolic improvements, including reductions in waist circumference, blood pressure, and glycemic markers, also largely reversed by week 120.

That same publication noted that body weight at week 120 was still modestly below baseline (an average net loss of about 5.6% from original weight), a number the popular press has sometimes used to soften the story. We think that reading misses the point entirely. The trajectory at week 120 was still heading upward. There is no reason from the biology to expect it to plateau.

The long-term data from STEP-5 (Garvey et al., Nature Medicine, 2022) provide the counter-narrative: patients who stayed on semaglutide 2.4 mg for 104 weeks maintained a mean weight loss of 15.2% from baseline, with continued cardiometabolic benefit. Garvey and colleagues wrote directly: "These results support the chronic use of semaglutide 2.4 mg for the long-term treatment of obesity." That language matters. It is not a suggestion for extended use in selected patients. It is a statement about the biology of what this drug is doing and what happens when it stops.

The FDA label for Wegovy (semaglutide 2.4 mg), updated 2024, reinforces this. The approved indication explicitly describes semaglutide as an adjunct to "a reduced-calorie diet and increased physical activity for chronic weight management." The word chronic appears in the indication itself, not in a footnote. That is a regulatory signal most prescribers have not translated into their patient conversations.

To put numbers in sequence: STEP-1 showed approximately 14.9% mean weight loss at week 68 on drug. Wilding et al. showed 11.6 percentage points of that regained by week 120 off drug. Garvey et al. showed 15.2% sustained at week 104 on drug. The comparison is nearly symmetrical. Continuity of treatment predicts continuity of benefit; discontinuation predicts near-complete reversal.

Mechanistically, this is not surprising. Semaglutide acts at GLP-1 receptors in the hypothalamus and brainstem to suppress appetite, slow gastric emptying, and modulate dopaminergic reward pathways tied to food-seeking behavior. When the drug leaves the system, those pathways return to their pre-treatment state. Obesity is, in the language of the American Heart Association's scientific statement on obesity pharmacotherapy, a "chronic, relapsing neurobiological disease," not a behavioral deficit correctable by a finite intervention. The STEP-1 extension data are simply the clinical expression of that neurobiology.

Where the consensus falls short

The dominant primary-care framing, GLP-1 as a "jump-start" before returning to lifestyle, does not come from nowhere. It reflects a genuine and understandable desire to limit drug exposure, reduce cost, and honor patient preferences for not being on a medication indefinitely. We take those concerns seriously. But the framing is not supported by the evidence, and it has a concrete cost: patients who discontinue expecting to sustain results through diet and exercise alone are not warned that the pharmacology will almost certainly work against them.

The lifestyle-continuation argument rests on a model in which the drug teaches the body new habits. That model is wrong. Wilding et al. showed that hunger scores, appetite, and food cravings all returned toward baseline after discontinuation, confirming that the behavioral changes observed on-drug were drug-mediated, not habit-formed. There is no "locking in" of a new appetite set-point. The body does not learn; the receptor signaling simply stops.

We also want to name a subtler problem. Some prescribers apply a time-limited framing selectively to patients they perceive as needing "motivation" or a "reset," often patients with class I or II obesity who appear to have "less far to go." This is worth examining critically. The STEP-1 and STEP-5 populations included participants across the BMI spectrum above 30 kg/m², and the regain pattern after discontinuation did not cluster among those with higher baseline BMI. The pharmacology is consistent regardless of how much a patient needs to lose.

The access and cost problem is real and should be addressed directly rather than papered over with an inaccurate framing. If a patient cannot sustain coverage for semaglutide, the honest conversation is: "If you stop this medication, most of the weight you've lost will likely return within a year, based on clinical trial data. Let's plan for that possibility, talk about what we'll do if coverage lapses, and think about whether there are lower-cost GLP-1 options or other chronic-weight-management strategies that can bridge gaps." That is categorically different from: "Let's use this to get you started and then see if you can maintain on your own."

The guidelines are beginning to catch up, but slowly. The Endocrine Society's clinical practice guideline on obesity pharmacotherapy acknowledges the chronic-disease model, and the American Association of Clinical Endocrinology (AACE) obesity guidelines have consistently framed obesity pharmacotherapy as potentially indefinite. Primary care has been slower to adopt this framing, and that is the gap we are most concerned about, because primary care prescribers now write the majority of GLP-1 prescriptions for obesity.

Our position

The HealthRX Medical Team holds this position: semaglutide for obesity should be initiated with explicit, documented counseling that the expected duration of therapy is indefinite, contingent on tolerability, access, and shared patient goals, and that discontinuation carries a high probability of substantial weight regain within 12 months.

We are not saying every patient must stay on semaglutide forever. Patients may choose to stop, may lose access, or may have intolerance. What we are saying is that the default framing must shift. The opening conversation should not be "let's try this for a year and see." It should be closer to: "This medication works the way a blood pressure medication works. It manages a chronic condition while you take it. The data show that stopping it leads to weight returning, usually substantially, within about a year. Knowing that, here is how we should plan together."

That framing change is not purely semantic. In our clinical judgment, it changes adherence, it changes how patients interpret weight regain if it occurs, and it changes how patients respond to access disruptions. A patient who was told the drug is chronic and then loses insurance coverage is better equipped to advocate, seek alternatives, and understand what is happening to their body than a patient who was told they were "done" and now experiences regain as personal failure.

We extend this beyond strict RCT support on one point: we believe the counseling framing itself affects outcomes. We do not have an RCT of "chronic framing vs. time-limited framing" as an intervention. We are making a judgment grounded in the behavioral medicine literature on illness beliefs and medication adherence, particularly the work connecting patient mental models of chronic disease to long-term engagement with treatment. That is a reasonable extrapolation, but readers should weigh it accordingly.

The SELECT trial (Lincoff et al., NEJM 2023) added a further dimension that strengthens our position: semaglutide reduced major adverse cardiovascular events by 20% in patients with overweight or obesity and established cardiovascular disease, independent of weight loss magnitude. That cardiovascular benefit also stops when the drug stops. Framing this as a short-course intervention means patients are not just losing weight benefit, they may be losing cardiovascular protection that an ongoing, evidence-supported therapy was providing.

The FDA's 2024 label update for Wegovy now includes the cardiovascular risk reduction indication for patients meeting SELECT criteria. A time-limited prescription frame is increasingly inconsistent with the full scope of what the FDA has sanctioned this drug to do.

Prescribers uncomfortable with indefinite framing should also be aware that the CDC's chronic disease data consistently show obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea, osteoarthritis) as drivers of morbidity that accumulate over years. A single year of weight loss followed by regain is not clinically neutral. The regained weight often carries with it recurrence of metabolic abnormalities, as shown in the cardiometabolic reversal data from Wilding et al..

What would change our mind

We would revise this position if a well-designed trial demonstrated that patients who complete 68 to 104 weeks of semaglutide therapy and then discontinue can sustain more than 50% of their weight loss at 24 months through structured lifestyle intervention alone, in a population representative of general primary-care patients (not highly selected, intensively supported participants). That trial does not exist. The only randomized evidence we have points in the opposite direction.

We would also update our counseling framework if novel evidence emerged showing that GLP-1 therapy produces durable hypothalamic plasticity, effectively resetting appetite regulation at a new set-point after a finite course. There is currently no human trial evidence for that mechanism. Animal model work does not transfer cleanly to clinical practice here.

Finally, a meaningful reduction in regain rates with structured high-intensity lifestyle transition programs, tested in RCTs with semaglutide users specifically, would complicate the picture and might support a "taper-and-transition" model for selected patients. We await that data.

The clinical implication that matters most is this: the next patient you sit down with who asks "how long will I be on this?" deserves an honest, evidence-grounded answer, not a reassuring vagueness. The STEP-1 extension data exist. They are not ambiguous. Patients who do not hear them before they start are not being protected from anxiety, they are being deprived of the information they need to make a real decision about their own care.

References

  • Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
  • Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. https://pubmed.ncbi.nlm.nih.gov/36280822/
  • Wegovy (semaglutide) prescribing information. FDA; 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
  • Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. https://www.nejm.org/doi/10.1056/NEJMoa2307563
  • Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(9):2180-2200. https://academic.oup.com/jcem/article/108/9/2180/7173265
  • American Association of Clinical Endocrinology obesity clinical practice guidelines. Endocrine Society. https://www.endocrine.org/clinical-practice-guidelines
  • Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001160
  • CDC. About chronic diseases. Centers for Disease Control and Prevention. https://www.cdc.gov/chronicdisease/about/index.htm